In the last trading session, 3.16 million TransCode Therapeutics Inc (NASDAQ:RNAZ) shares changed hands as the company’s beta touched 1.54. With the company’s per share price at $0.42 changed hands at $0.04 or 11.00% during last session, the market valuation stood at $9.85M. RNAZ’s last price was a discount, traded about -15692.86% off its 52-week high of $66.33. The share price had its 52-week low at $0.22, which suggests the last value was 47.62% up since then. When we look at TransCode Therapeutics Inc’s average trading volume, we note the 10-day average is 4.9 million shares, with the 3-month average coming to 7.60 million.
TransCode Therapeutics Inc (NASDAQ:RNAZ) trade information
Instantly RNAZ was in green as seen at the end of in last trading. With action 40.60%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -87.48%, with the 5-day performance at 40.60% in the green. However, in the 30-day time frame, TransCode Therapeutics Inc (NASDAQ:RNAZ) is -18.88% down. Looking at the short shares, we see there were 1.04 million shares sold at short interest cover period of 0.07 days.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 48.04%. The 2025 estimates are for TransCode Therapeutics Inc earnings to increase by 96.54%, but the outlook for the next 5-year period is at 82.79% per year.
RNAZ Dividends
TransCode Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Apr-14.
TransCode Therapeutics Inc (NASDAQ:RNAZ)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.15% of TransCode Therapeutics Inc shares while 0.71% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 0.71%.
Among Mutual Funds, the top two as of Jan 31, 2025 were Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Total Market Index Fund . With 2.83 shares estimated at $1194.0 under it, the former controlled 0.01% of total outstanding shares. On the other hand, Fidelity Concord Street Trust-Fidelity Total Market Index Fund held about 0.01% of the shares, roughly 1.18 shares worth around $497.0.
